Actually, the P3 did. It just did it by different methods and shorts do not want to recognize that regulators don't have hard and fast rules for that. Using the third-party to put that together, without looking at any results, before the trial was unblinded, was effectively and likely viewed as the SAME THING. Plus this is a rare disease. The notion that it wasn't, is a bogeyman story you guys tell the naive, who you hope will believe anything you say.
Market Data 
Markets 
AI
